Opinions of Healthcare Providers About a European Neuromodulation Register

• Sponsor: Moens Maarten (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT06030973
• Collaborator: Vrije Universiteit Brussel (Other)
• Enrollment: 100
• Location: 1
• Anticipated Duration (Days): 2
• Patients Per Site Per Month: 1521.9

Study Details

Study Description

Brief Summary

The goal of this online survey is to gain further insights in the needs and burden for a European registry for neuromodulation, according to healthcare providers.

Condition or Disease	Intervention/Treatment	Phase
Registry; Neuromodulation; Survey	Behavioral: Filling in an online survey

Study Design

• Study Type: Observational
• Anticipated Enrollment: 100 participants
• Observational Model: Case-Only
• Time Perspective: Cross-Sectional
• Official Title: Opinions of Healthcare Providers About a European Neuromodulation Register: an Online Survey
• Actual Study Start Date: Aug 31, 2023
• Anticipated Primary Completion Date: Sep 2, 2023
• Anticipated Study Completion Date: Sep 2, 2023

Arms and Interventions

Arm	Intervention/Treatment
Healthcare professionals involved in neuromodulation	Behavioral: Filling in an online survey; Professionals are asked to complete questions regarding 1) the degree of current participation in a registry, 2) the need for a European registry, 3) the items that should be collected and 4) access to the European registry.

Outcome Measures

Primary Outcome Measures

1. Healthcare providers their current degree of participation in a registry for neuromodulation. [Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.]

   Degree of participation in a registry for neuromodulation (question).

2. Healthcare providers their need for a European registry. [Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.]

   Underlying reasons on why a European registry is needed, or not needed (question).

3. Items that should be included in a registry for neuromodulation, according to healthcare providers. [Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.]

   Items that should be collection within a registry, evaluated with a multiple choice question.

4. Access regulations to European registry for neuromodulation, according to healthcare providers. [Cross-sectional evaluation during 3th Joint Congress of the INS European Chapters (e-INS 2023) in Hamburg in August-September 2023.]

   Access regulations, evaluated with a multiple choice question.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain (including but not limited to anesthesiologists, neurosurgeons, nurses).

Exclusion Criteria:

• Not involved in management of chronic pain through neuromodulation.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Congres Center	Hamburg		Germany

Sponsors and Collaborators

• Moens Maarten
• Vrije Universiteit Brussel

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Moens Maarten, Principal Investigator, Universitair Ziekenhuis Brussel
• ClinicalTrials.gov Identifier: NCT06030973
• Other Study ID Numbers: PROLOGUE
• First Posted: Sep 11, 2023
• Last Update Posted: Sep 11, 2023
• Last Verified: Sep 1, 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Sep 11, 2023